RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
27.555
-0.275 (-0.988%)
As of 10:33AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close27.830
Open27.690
Bid0.000 x 0
Ask0.000 x 0
Day's Range27.530 - 27.690
52 Week Range27.510 - 36.820
Volume1,200,687
Avg. Volume2,260,500
Market Cap188.939B
Beta0.53
PE Ratio (TTM)21.05
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.11 (3.99%)
Ex-Dividend Date2018-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Roche CEO 'Very Confident' on European Sales Growth
    Bloomberg Video4 hours ago

    Roche CEO 'Very Confident' on European Sales Growth

    Apr.26 -- Severin Schwan, chief executive officer at Roche Holding AG, discusses first-quarter results, the impact of new medicines on European sales and the company's M&A strategy. He speaks with Bloomberg's Nejra Cehic on "Bloomberg Markets: European Open."

  • Here’s why Amazon won’t go into pharma: hedge fund billionaire
    Yahoo Finance Video2 days ago

    Here’s why Amazon won’t go into pharma: hedge fund billionaire

    Larry Robbins, CEO of Glenview Capital Management, told investors he doesn’t expect Amazon to move into the drug space. Yahoo Finance’s Alexis Christoforous, Melody Hahm, and Julia La Roche discuss his reasoning.

  • Reuters4 hours ago

    Biosimilar worries takes shine off Roche's guidance hike

    Cheaper copies of Roche's (ROG.S) Rituxan toppled the blood cancer drug from its perch as the Swiss company's top seller in the first quarter, unsettling some investors despite a stronger-than-expected performance from new medicines. "The key focus for today looks likely to be the big hit from biosimilars versus the decent performance from Ocrevus and Hemlibra, with the former likely to dominate," Deutsche Bank analyst Tim Race said, calling Rituxan's drop in Europe "stunning". Roche Chief Executive Severin Schwan remained upbeat.

  • Reuters4 hours ago

    UPDATE 4-Biosimilar worries takes shine off Roche's guidance hike

    Cheaper copies of Roche's Rituxan toppled the blood cancer drug from its perch as the Swiss company's top seller in the first quarter, unsettling some investors despite a stronger-than-expected performance from new medicines. Robust demand for new treatments such as Ocrevus for multiple sclerosis and Hemlibra for haemophilia A helped the world's biggest cancer drugs maker to nudge up its full-year sales and profit forecasts on Thursday. "The key focus for today looks likely to be the big hit from biosimilars versus the decent performance from Ocrevus and Hemlibra, with the former likely to dominate," Deutsche Bank analyst Tim Race said, calling Rituxan's drop in Europe "stunning".

  • Roche CEO 'Very Confident' on European Sales Growth
    Bloomberg4 hours ago

    Roche CEO 'Very Confident' on European Sales Growth

    Severin Schwan, chief executive officer at Roche Holding AG, discusses first-quarter results, the impact of new medicines on European sales and the company's M&A strategy. He speaks with Bloomberg's Nejra ...

  • The Wall Street Journal8 hours ago

    [$$] Roche Raises Outlook After Sales Rise

    AG (ROG.EB) raised its outlook on Thursday after first-quarter sales increased, buoyed by the pharmaceutical company’s multiple-sclerosis drug Ocrevus and its HER2 breast-cancer drugs. Switzerland-based Roche said sales rose to 13.6 billion Swiss francs ($13.8 billion) from CHF12.9 billion, beating expectations. According to a FactSet consensus estimate, Roche was forecast to post sales for CHF13.35 billion.

  • Bloomberg9 hours ago

    Roche Lifts Forecast as Bet Outside Cancer Starts to Pay Off

    Roche Holding AG’s bet on fields outside cancer is starting to pay off as the Swiss drugmaker boosted its forecast even as sales of one of its top drugs collapsed in Europe.

  • Financial Times9 hours ago

    [$$] Roche upgrades growth forecast after new drugs boost sales

    Swiss pharmaceuticals group Roche has revised its 2018 sales growth forecast higher after new drugs helped power a 6 per cent rise in the first quarter compared with a year earlier. The Basel-based group said on Thursday it now expected full year sales growth in the “low single-digit” range in constant exchange rates. Roche’s total sales were SFr 13.6bn in the first three months of the year.

  • Gilead Sciences has a Strong Oncology Research Program
    Market Realistyesterday

    Gilead Sciences has a Strong Oncology Research Program

    Gilead Sciences (GILD) is currently studying a combination of anti-MMP-9 (anti-matrix metalloproteinase-9) antibody andecaliximab with modified FOLFOX 6 in a Phase 3 trial as a therapy for treatment-naïve advanced gastric or GAMMA-1 (gastroesophageal junction adenocarcinoma) patients. The company also expects to conclude its Phase 2 trial comparing an andecaliximab-nivolumab combination with a nivolumab monotherapy in gastric cancer in 2018. If these trials prove successful, Gilead Sciences could emerge as major competition for other gastric cancer therapy players such as Eli Lilly (LLY) and Roche (RHHBY).

  • Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
    Zacks2 days ago

    Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

    Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

  • Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
    Zacks3 days ago

    Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

    Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.

  • Reuters3 days ago

    FDA declines to approve Pfizer biosimilar of Roche's cancer drug

    Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision.

  • MarketWatch3 days ago

    Pfizer says FDA failed to approve Herceptin biosimilar

    Pfizer Inc. said early Monday that the Food and Drug Administration failed to approve its trastuzumab biosimilar, intended as a lower-cost version of Roche's cancer drug Herceptin. The FDA asked for more ...

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks6 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • Moody's7 days ago

    Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising

    The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.

  • Roche Hemophilia Drug Gets Breakthrough Therapy Designation
    Zacks8 days ago

    Roche Hemophilia Drug Gets Breakthrough Therapy Designation

    The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

  • How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
    Market Realist8 days ago

    How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017

    In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters8 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters8 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters8 days ago

    GSK grabs Roche cancer expert to lead pharma pipeline deals

    GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...

  • AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
    Market Realist9 days ago

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.

  • Reuters9 days ago

    Roche's Hemlibra gets speedy FDA review for wider use

    Roche's hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company's plans to muscle in on turf dominated by rivals including Shire. The U.S. Food and Drug Administration granted breakthrough therapy designation to the medicine to be used in people who have not yet developed resistance to conventional treatments, called inhibitors, Roche said on Tuesday. Hemlibra is already approved for people with inhibitors, though Shire is fighting Roche in court seeking to halt expanded use of the medicine.

  • How AbbVie’s Humira Performed in 4Q17 and 2017
    Market Realist10 days ago

    How AbbVie’s Humira Performed in 4Q17 and 2017

    AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.

  • Upadacitinib Could Drive AbbVie’s Long-Term Growth
    Market Realist10 days ago

    Upadacitinib Could Drive AbbVie’s Long-Term Growth

    In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.

  • Roche on Damage Control after Hemlibra Patient Deaths
    Market Realist13 days ago

    Roche on Damage Control after Hemlibra Patient Deaths

    The news that five patients on Roche’s (RHHBY) hemophilia drug Hemlibra died triggered the company’s stock to decline ~2% on March 28, 2018. It also announced that it has received a favorable ruling in a Japanese court in a patent-infringement litigation with Shire (SHPG).